Personal profile
Fingerprint
Dive into the research topics where Keunchil Park is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC
Paz-Ares, L., Veillon, R., Majem, M., Zhou, C., Tang, K. J., Kim, S. W., Richardson, G., Girard, N., Sanborn, R. E., Mansfield, A. S., Park, K., Schuchard, J., Diels, J., Sermon, J., Bhattacharya, A., Lorenzini, P., Wortman-Vayn, H., Knoblauch, R. E., Agrawal, T. & Baig, M. & 2 others, , Mar 2026, In: Lung Cancer. 213, 108788.Research output: Contribution to journal › Article › peer-review
-
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study
Sanborn, R. E., Zhou, C., Tang, K. J., Cho, B. C., Cheng, S., Popat, S., Ono, A., Lu, S., Majem, M., Aguilar, A., Del Rosario Garcia Campelo, M., Hayashi, H., Lee, K. Y., Lee, S. H., Delmonte, A., Alatorre-Alexander, J., Richardson, G., Santos, V., Dooms, C. & Sabari, J. K. & 19 others, , Nov 2025, In: Targeted Oncology. 20, 6, p. 979-989 11 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
Wang, Y., Safi, M., Hirsch, F. R., Lu, S., Peters, S., Govindan, R., Rosell, R., Park, K. & Zhang, J. J., Mar 2025, In: Nature Reviews Clinical Oncology. 22, 3, p. 200-214 15 p., 39.Research output: Contribution to journal › Review article › peer-review
37 Link opens in a new tab Scopus citations -
Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer
Leighl, N. B., Trigo, J., Park, K., Lee, S. H., Girard, N., Viteri, S., Garrido, P., Krebs, M. G., Thayu, M., Knoblauch, R. E., Xie, J., Bauml, J. M., Schnepp, R. W., Londhe, A., Xia, Y., Mahadevia, P. J. & Cho, B. C., Jul 2025, In: Lung Cancer. 205, 108579.Research output: Contribution to journal › Article › peer-review
Open Access3 Link opens in a new tab Scopus citations -
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC
Nakagawa, K., Garon, E. B., Seto, T., Nishio, M., Aix, S. P., Paz-Ares, L., Chiu, C. H., Park, K., Novello, S., Nadal, E., Nishino, K., Yoh, K., Shih, J. Y., Chik, J. Y. K., Moro-Sibilot, D., Puri, T., Chacko Varughese, S., Frimodt-Moller, B., Visseren-Grul, C. & Reck, M., Apr 2025, In: Journal of Thoracic Oncology. 20, 4, p. 487-499 13 p.Research output: Contribution to journal › Article › peer-review
Open Access17 Link opens in a new tab Scopus citations